Sarepta Therapeutics gains on S&P MidCap inclusion

Shockwave Medical

30/05/2024 15:35

** Shares of Sarepta Therapeutics  SRPT.O  up 6.1% at
$123.32 early Thurs as co set to join S&P MidCap 400 index
 .IDX  next week
    ** Stock tracking biggest daily pct gain since Apr 24
    ** SRPT to replace Shockwave Medical Inc  SWAV.O  in IDX
effective Mon, Jun 1, according to S&P Dow Jones Indices
announcement
    ** Shockwave being acquired by Johnson & Johnson  JNJ.N  in
$13 bln deal
    ** Sarepta has current market cap of approx $11.7 bln, LSEG
data shows
    ** Earlier this month, Sarepta said U.S. FDA to decide on
application seeking traditional approval for Elevidys, its
muscle-wasting disorder gene therapy by June 21
    ** With move on the session, SRPT up ~28% YTD and up ~50%
over the past six months
    ** Avg rating among 22 analysts covering stock is "buy" and
median PT is $168 - LSEG

 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-646-279-6380))